Selected Publications

Anaveon presents clinical trial OMNIA-2

ASCO annual Meeting. 2023 Jun 2-6

Anaveon Presents Trial in Progress Data for OMNIA-1

ASCO Annual Meeting. 2023 June 2-6

Anaveon presents ANV600, a novel development compound

AACR Annual Meeting. 2023 Apr 14-19

ANV419 is a novel CD122-biased IL-2/anti-IL-2 fusion protein with potent CD8 T cell and NK cell stimulating capacity that shows additive efficacy in combination with checkpoint inhibitors and treatments acting through antibody dependent cellular cytotoxicity

ESMO Congress. 2022 Sep 9-13

ANV419, an IL-2R-beta-gamma targeted antibody-IL-2 fusion protein, induces selective effector cell proliferation in patients with progressed cancer

AACR Annual Meeting. 2022 Apr 8-13

Favorable pre-clinical safety profile of the novel not-alpha IL-2 agonist ANV419 supports first in human clinical development

SITC Annual Meeting. 2021 Nov 10-14

ANV419 is a novel CD122 selective IL 2/anti IL 2 antibody fusion protein with potent CD8+ T cell
and NK cell stimulatory function in vitro and in vivo

SITC Annual Meeting. 2020 Nov 9-14

Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2

Sci Transl Med. 2016 Nov 30;8(367):367ra166.

Antibodies to Interleukin-2 Elicit Selective T Cell Subset Potentiation through Distinct Conformational Mechanisms

Immunity. 2015 May 19;42(5):815-25

Improved IL-2 immunotherapy by selective stimulation of IL-2 receptors on lymphocytes and endothelial cells

Proc Natl Acad Sci U S A. 2010 Jun 29;107(26):11906-11

Selective stimulation of T cell subsets with antibody-cytokine immune complexes

Science. 2006 Mar 31;311(5769):1924-7